RGLS Key Statistics, Chart & Performance
The current stock price of RGLS is 8.16 USD. In the past month the price increased by 3.42%. In the past year, price increased by 357.14%.
RGLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About RGLS
Company Profile
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Company Info
REGULUS THERAPEUTICS INC
4224 Campus Point Court, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Joseph P. Hagan
Employees: 34
Phone: 18582026300
REGULUS THERAPEUTICS INC / RGLS FAQ
Can you describe the business of REGULUS THERAPEUTICS INC?
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The company went IPO on 2012-10-04. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
What is the current price of RGLS stock?
The current stock price of RGLS is 8.16 USD. The price increased by 0.25% in the last trading session.
Does REGULUS THERAPEUTICS INC pay dividends?
RGLS does not pay a dividend.
What is the ChartMill rating of REGULUS THERAPEUTICS INC stock?
RGLS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about REGULUS THERAPEUTICS INC (RGLS) stock?
12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16.
What is the ownership structure of REGULUS THERAPEUTICS INC (RGLS)?
You can find the ownership structure of REGULUS THERAPEUTICS INC (RGLS) on the Ownership tab.
RGLS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RGLS. When comparing the yearly performance of all stocks, RGLS is one of the better performing stocks in the market, outperforming 99.47% of all stocks.
RGLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RGLS. No worries on liquidiy or solvency for RGLS as it has an excellent financial health rating, but there are worries on the profitability.
RGLS Financial Highlights
Over the last trailing twelve months RGLS reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.51% | ||
| ROE | -68.85% | ||
| Debt/Equity | 0 |
RGLS Forecast & Estimates
12 analysts have analysed RGLS and the average price target is 8.67 USD. This implies a price increase of 6.25% is expected in the next year compared to the current price of 8.16.